Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.11
$4.65
$13.13
$1.10B1.471.18 million shs19.38 million shs
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14.19
-2.2%
$14.89
$8.26
$19.41
$1.24B-0.011.30 million shs1.61 million shs
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
$4.99
+1.6%
$5.25
$3.75
$11.00
$283.70M1.961.73 million shs1.32 million shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$15.75
+3.6%
$19.93
$14.87
$48.24
$1.01B1.481.49 million shs1.83 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.08%+59.82%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-2.21%+5.27%+0.71%+3.43%+10.60%
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
+1.63%-4.22%-5.13%-4.04%-47.58%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
+3.62%-0.63%-21.41%-6.58%-66.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.1908 of 5 stars
4.50.00.00.01.84.20.6
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
2.5715 of 5 stars
3.62.00.00.04.40.00.6
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4.0936 of 5 stars
4.21.00.04.92.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.00
Buy$26.8989.49% Upside
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
3.25
Buy$9.5090.38% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.33
Hold$32.71107.71% Upside

Current Analyst Ratings Breakdown

Latest NNOX, FNA, TNDM, and LQDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/9/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Sell$24.00 ➝ $14.00
6/16/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$24.00
6/12/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.00
6/11/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $23.00
6/6/2025
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/2/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $35.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14M86.65N/AN/A$0.91 per share15.59
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
$11.28M25.56N/AN/A$3.27 per share1.53
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$940.20M1.12N/AN/A$4.01 per share3.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
-$53.52M-$0.90N/AN/AN/A-472.19%-30.92%-27.73%8/19/2025 (Estimated)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%8/6/2025 (Confirmed)

Latest NNOX, FNA, TNDM, and LQDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.43N/AN/AN/A$3.90 millionN/A
8/6/2025Q2 2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.40N/AN/AN/A$238.39 millionN/A
5/22/2025Q1 2025
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
-$0.23-$0.21+$0.02-$0.21$3.98 million$3.00 million
5/8/2025Q1 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million
4/30/2025Q1 2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
N/AN/AN/AN/AN/A
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
2.08
2.93
2.91
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
N/A
5.30
5.16
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.99
2.30
1.81

Institutional Ownership

CompanyInstitutional Ownership
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
64.54%
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
21.49%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
26.50%
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
7.74%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
5085.49 million62.83 millionOptionable
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
19057.78 million53.31 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,65066.61 million65.34 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Paragon 28 stock logo

Paragon 28 NYSE:FNA

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Liquidia Technologies stock logo

Liquidia Technologies NASDAQ:LQDA

$14.19 -0.32 (-2.21%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$14.09 -0.10 (-0.70%)
As of 07:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Nano-X Imaging stock logo

Nano-X Imaging NASDAQ:NNOX

$4.99 +0.08 (+1.63%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$4.99 0.00 (0.00%)
As of 07:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.

Tandem Diabetes Care stock logo

Tandem Diabetes Care NASDAQ:TNDM

$15.75 +0.55 (+3.62%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$15.50 -0.25 (-1.61%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.